ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Use Of Coreg(R) (Carvedilol) At Hospital Discharge Associated With Improved Survival In Patients With Heart Failure, New Analysis
Patients with heart failure
who were prescribed the beta-blocking agent Coreg(R) (carvedilol) at the time
of their hospital discharge showed improved survival rates at 60-90 days,
according to results of a new analysis from the heart failure registry,
OPTIMIZE-HF (Organized Program To Initiate life-saving treaMent In
hospitaliZEd patients with Heart Failure). Presented today at the 55th Annual
Scientific Session of the American College of Cardiology, the analysis also
showed that COREG was associated with improved treatment rates among patients
with heart failure, a condition often caused by hypertension and heart attacks
that results in the heart failing to pump enough blood to the rest of the
body.
OPTIMIZE-HF, funded by GlaxoSmithKline (NYSE: GSK), is the only
hospital-based heart failure registry with 60-90 day follow-up data on this
patient population, and is the second largest heart failure registry in the
country.
Data were collected at 60 to 90 days following hospital discharge on
patients with heart failure to measure the associations with clinical outcomes
in eligible patients with left ventricular systolic dysfunction (LVSD) who
received COREG prior to hospital discharge versus those eligible but who
received no beta-blocker at discharge. Of the 2,720 pts with LVSD, 2,373
(87.2%) were eligible to receive a beta-blocker at discharge. COREG was
prescribed at discharge in 1,146 patients, 94.2 percent of whom remained on
therapy for the duration of their follow-up period.
The analysis showed that patients prescribed COREG at hospital discharge
had a significantly decreased risk for death and death or re-hospitalization
without early risk for re-current worsening heart failure.
"This analysis adds to the evidence supporting the benefits and
tolerability of prescribing carvedilol at hospital discharge for patients
admitted with heart failure," said Gregg C. Fonarow, M.D., chairman of the
OPTIMIZE-HF Committee and director of Ahmanson - UCLA Cardiomyopathy Center in
Los Angeles. "Based on this analysis and earlier studies, carvedilol should
be started when medically advisable at the time of hospital discharge in all
eligible heart failure patients since the difference in survival and
re-hospitalizations emerges in just weeks among patients who receive
carvedilol as opposed to those who don't have a beta-blocker added to their
treatment regimen."
A recent study published in Circulation, the Journal of the American Heart
Association, found that the incidence of heart failure in the U.S. among older
adults increased by epidemic proportion from the 1970s to the 1990s. The
Circulation study concluded that, "To address this growing public health
problem, in the short run, we need to strive for optimal provision of
effective management for newly diagnosed heart failure to enhance survival and
reduce hospitalizations."
The use of COREG in patients with heart failure is supported by
evidence-based guidelines, including the recently updated ACC/AHA Joint
Guidelines for the Diagnosis and Management of Chronic Heart Failure in the
Adult.
About OPTIMIZE-HF
Funded by GlaxoSmithKline and launched in 2003, OPTIMIZE-HF is a national
hospital-based heart failure care improvement program and Web-based registry
aimed to improve patient outcomes by implementing evidence-based,
guideline-driven heart failure management practices. The second largest heart
failure quality of care program ever implemented and the only one with
60-90 day follow-up data, OPTIMIZE-HF further investigated barriers to the
initiation and maintenance of evidence-based therapies among approximately
50,000 patients from all regions in the U.S. with a primary or secondary
discharge diagnosis of heart failure. Approximately 270 hospitals worked
collaboratively to measure and improve the management of patients with heart
failure.
About COREG
COREG is marketed by GlaxoSmithKline in the United States and is the only
beta-blocking agent FDA approved to improve survival in mild to severe heart
failure and is the only beta-blocker approved for patients who suffered a
heart attack that reduced how well the heart pumps.
Specific indications are:
-- COREG is approved for the treatment of hypertension, which is also
known as high blood pressure.
-- COREG is approved to reduce the risk of death in patients who
suffered a heart attack that reduced how well the heart pumps.
-- COREG is approved to increase survival in mild to severe heart
failure patients.
Important Safety Information
It is important for patients to take their medicine every day as directed
by their doctors or health care providers. Patients taking COREG should avoid
stopping therapy abruptly. With certain beta-blocking agents, stopping therapy
abruptly has led to chest pain and, in some cases, heart attack. If their
doctor decides that they should stop taking COREG, their doctor or health care
provider may slowly reduce their doses over a period of time before stopping
it completely.
Some common side effects associated with COREG include shortness of
breath, a slow heartbeat, weight gain, fatigue, hypotension, dizziness or
faintness. People taking COREG who have any of these symptoms should call
their doctor. Additionally, if patients experience fatigue or dizziness, they
should sit or lie down and avoid driving or hazardous tasks. Beta-blockers
may mask the symptoms of low blood sugar or alter blood sugar levels. People
with diabetes should report any changes in blood sugar levels to their
physician. Contact lens wearers may produce fewer tears or have dry eyes. As
with any medicine, patients taking COREG should also first tell their doctor
what other medications they are taking.
As with any medicine, there are some people who should not take COREG.
The
people who should not take COREG include those with severe heart failure who
are hospitalized in the intensive care unit. Also, people who require certain
intravenous medications that help support their circulation (inotropic
medications) should not receive COREG. Other people who should not take COREG
are those who are prone to asthma or other breathing problems, those with a
very slow heartbeat or heart that skips a beat (irregular heartbeat) and those
with liver problems. For more information on COREG, visit
http://www.coreg.com.
About Heart Failure
Heart failure is a progressive condition in which the heart muscle becomes
weakened from conditions such as high blood pressure or an event such as a
heart attack, and gradually loses the ability to pump enough blood to supply
the body sufficiently. Heart failure is common but under-recognized and often
misdiagnosed. Risk factors for heart failure include high blood pressure,
prior heart attack, history of heart murmurs, enlarged heart, diabetes and
family history of enlarged heart. Heart failure affects nearly five million
Americans and 550,000 people are newly diagnosed with the condition each year.
From 1990 to 1999, the number of hospitalizations for heart failure increased
from 810,000 to over one million. Even though clinical guidelines recommend
that all patients with stable heart failure be on beta-blocker therapy, many
are not being treated with or discharged on a beta-blocker. This may lead to
a significant number of unnecessary deaths and costly rehospitalizations for
patients with heart failure.
About GlaxoSmithKline
GlaxoSmithKline -- one of the world's leading research-based
pharmaceutical and healthcare companies -- is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer.
GlaxoSmithKline
http://www.coreg.com
http://www.gsk.com
Utilizarea de Coreg (R) (Carvedilol) de la Spitalul de descãrcare de gestiune asociate cu ameliorare a supravieþuirii la pacienþii cu insuficienþã cardiacã, noi de analizã - Use Of Coreg(R) (Carvedilol) At Hospital Discharge Associated With Improved Survival In Patients With Heart Failure, New Analysis - articole medicale engleza - startsanatate